2Seventy Bio Inc (TSVT) USD0.0001
- Add to watchlist
- This stock can be held in a
Business summary
2seventy bio, Inc. is a cell and gene therapy company, which is focused on the research, development, and commercialization of transformative treatments for cancer. The Company's approach combines its knowledge in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop targeted cellular therapies for patients with cancer. Its advancing multiple clinical programs includes SC-DARIC33, for the treatment of pediatric patients with relapsed and refractory acute myeloid leukemia (AML), and bbT369, for the treatment of patients with B-cell non-Hodgkins lymphoma (B-NHL), as well as multiple preclinical programs, consisting of bbT4015, an engineered CAR T cell therapy targeting MUC16. Additionally, together with its partner Bristol Myers Squibb, the Company delivers Abecma to multiple myeloma patients in the United States.
Contact details
Important dates
General stock information
- Short code:
- TSVT
- ISIN:
- US9013841070
- Market cap:
- $254.50 million
- Shares in issue:
- 51.31 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- NASDAQ Comb. Composite
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.